What Are the Benefits and Risks of Tirzepatide Injectable with B12?
Tirzepatide injectable with B12 is a compounded weekly shot that puts tirzepatide and a B12 form in the same vial. It is not FDA-approved. On March 12, 2026, Eli Lilly reported an impurity from a chemical reaction between tirzepatide and B12 in compounded samples.
Written for Dominia Health education · Reviewed by Ariel Bowerman, BSN, R.N. · Last evidence check: September 2026
Tirzepatide injectable with B12 is a compounded weekly shot that puts tirzepatide and a B12 form (cyanocobalamin, methylcobalamin, or hydroxocobalamin) in the same vial. It is not FDA-approved. Approved pens do not contain B12. SURMOUNT-1 results at 5–15 mg do not automatically apply to this mix. On March 12, 2026, Eli Lilly reported an impurity from a chemical reaction between tirzepatide and B12 in compounded samples.
This page covers compounded injectable tirzepatide + B12 at standard strengths and the lower-dose "microdose" version, which has its own section: Microdose option: what's different.
Last evidence check: September 2026. No dedicated randomized trial of same-vial tirzepatide plus B12 has been published, at standard or microdose strengths.
What Is in the Vial
A compounded vial is intended to contain tirzepatide plus B12. Approved products start at 2.5 mg weekly and maintain at 5–15 mg. Compounded strengths vary. Multi-dose vials raise sterility questions after the first puncture. Use only the instructions from the prescriber and pharmacy. Do not convert internet "units."
Why Clinics Add B12 Instead of Giving It Separately
Clinics often say B12 may help energy or offset low B12. B12 deficiency is a real, separate issue. Same-vial mixing is not the same as a B12 tablet or a separate B12 shot. Ingredient evidence ≠ combination evidence. There is no established trial showing that same-vial B12 improves weight loss.
What Is Proven vs. Unproven
| Item | FDA-approved tirzepatide | Compounded injectable + B12 |
|---|---|---|
| Status | FDA-approved (Mounjaro, Zepbound) | Not FDA-approved |
| Typical weekly dose | Start 2.5 mg; maintain 5–15 mg | Varies by pharmacy; "microdose" vials usually below 2.5 mg |
| Weight-loss evidence | SURMOUNT-1: about 15–21% at 72 weeks at 5–15 mg | No dedicated RCTs of this mix |
| B12 in same syringe | No | Yes; compatibility not FDA-reviewed |
| 2026 impurity signal | Not applicable | Reported in tested B12 combinations |
SURMOUNT-1 (Jastreboff et al., NEJM, June 4, 2022): −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) versus −3.1% placebo at week 72. Those figures describe FDA-approved tirzepatide at studied doses — not a compounded vial with B12.
Risks That Apply to Any Tirzepatide
Common gastrointestinal effects were the main adverse events in SURMOUNT-1 and were mostly mild to moderate during dose escalation.
| Effect (SURMOUNT-1) | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Nausea | 24.6% | 33.3% | 31.0% | 9.5% |
| Diarrhea | 18.7% | 21.2% | 23.0% | 7.3% |
| Constipation | 16.8% | 17.1% | 11.7% | 5.8% |
| Vomiting | 8.3% | 10.7% | 12.2% | 1.7% |
| Stopped drug for an AE | 4.3% | 7.1% | 6.2% | 2.6% |
Source: Lilly SURMOUNT-1 disclosure of the NEJM data, June 4, 2022.
Serious labeled risks include pancreatitis, gallbladder disease, dehydration/kidney injury, hypoglycemia with certain diabetes drugs, and a boxed warning about thyroid C-cell tumors in rodents. Avoid with MTC or MEN2.
Risks Unique to Same-Vial B12
On March 12, 2026, Lilly's open letter stated that testing of compounded tirzepatide–B12 products found "significant levels of an impurity that results from a chemical reaction between tirzepatide and B12." Lilly wrote that nothing is known about that impurity's short- or long-term effects, receptor binding, toxicity, or immune reactions. MedPage Today reported that some tested samples contained as little as 43% of the labeled dose.
The Alliance for Pharmacy Compounding said the same day that Lilly had not published enough sample-handling detail for outsiders to judge the finding. That disagreement is part of the record; it does not make the combination FDA-approved.
FDA: compounded drugs are not reviewed for safety, effectiveness, or quality before marketing, and should be used only when an approved drug cannot meet the need.
Research-use-only vials sold for people are not recommended.
Who Might Discuss This with a Prescriber
A clinician may discuss FDA-approved tirzepatide if you meet labeled criteria. Same-vial B12 is a different product with a 2026 compatibility question. Avoid MTC/MEN2, relevant allergy, and research-only listings. A history of pancreatitis or other active issues may also rule it out, and pregnancy decisions belong with the clinician.
How This Differs from Zepbound or Mounjaro
Approved pens have no B12 in the device. Compounded is not a generic. Brand names appear here only because regulators and Lilly used them.
Microdose Option: What's Different
Labeled tirzepatide for weight management starts at 2.5 mg once weekly and is raised toward 5, 10, or 15 mg. "Microdose" is not one of those steps and has no FDA definition: compounded microdose + B12 vials are usually prepared below the 2.5 mg start, a range that was never the efficacy dose in SURMOUNT-1.
- What the evidence covers: SURMOUNT-1 tested 5, 10, and 15 mg. Nothing in that trial describes weight change below 2.5 mg, and no study has tested a microdose with B12 in the same vial.
- What does not change: Lilly's letter concerned tirzepatide–B12 mixes in general and did not single out a strength, so a lower dose is no reason to assume the impurity and potency questions go away. Labeled tirzepatide risks and multi-dose-vial handling risks also carry over.
- Who it is discussed for: adults already being evaluated for medical weight management who understand that this mix is compounded, that microdose is not a studied SURMOUNT dose, and that B12 in the same vial carries a 2026 compatibility question. The prescriber evaluates. This page does not.
From Our Founders
"I read Lilly's March 12, 2026 letter next to the SURMOUNT-1 tables. The 15–21% figures are for approved 5–15 mg pens without B12 in the syringe, not for any compounded B12 vial. Talk to your provider about which product you would actually inject." — Ariel Bowerman, BSN, R.N.
Frequently Asked Questions
What are the benefits and risks of tirzepatide injectable with B12? Benefits are inferred from approved tirzepatide, not proven for this mix. Risks include usual GI effects plus the impurity and potency concerns Lilly described in March 2026.
Is a tirzepatide–B12 vial FDA-approved? No. Compounded drugs are not FDA-approved, at standard or microdose strength.
Does B12 improve weight loss with tirzepatide? That has not been established. Do not treat B12 as a weight-loss booster.
What counts as a tirzepatide "microdose"? Clinics usually mean a weekly amount below the 2.5 mg labeled start. It is not an FDA-defined dose. See Microdose option: what's different.
Is a separate B12 product an option? A clinician can treat B12 deficiency with a separate product. Same-vial mixing is what Lilly tested.
What did Eli Lilly report about tirzepatide mixed with B12? On March 12, 2026, it reported an impurity from a tirzepatide–B12 reaction with unknown human risks; press coverage also described under-strength samples.
How often did nausea occur with approved tirzepatide? In SURMOUNT-1, nausea occurred in about 25–33% on 5–15 mg approved tirzepatide. Those are not rates for this compounded mix.
Who should skip compounded tirzepatide with B12? People with MTC/MEN2, relevant allergies, and anyone offered a research-only vial. A clinician decides the rest.
Is compounded tirzepatide the same as Zepbound or Mounjaro? No.
Bottom Line
FDA-approved tirzepatide at 5–15 mg has established trial data. Compounded injectable with B12 is not FDA-approved, carries a March 2026 same-vial impurity concern, and in its microdose form sits below the labeled start. Branded trial results do not automatically transfer. Do not treat B12 as a weight-loss booster.
So what? Ask whether you would receive an approved pen or a compounded B12 vial — and whether B12 can be given separately.
Have questions about medical weight management? Talk with a licensed healthcare provider. To learn more or request a consultation, visit Dominia Health.
Sources:
- Jastreboff AM, et al. SURMOUNT-1. NEJM 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Lilly SURMOUNT-1 press release. https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine
- Lilly open letter, March 12, 2026. https://investor.lilly.com/news-releases/news-release-details/open-letter-eli-lilly-and-company-warning-potential-patient
- Reuters — Lilly impurity warning. https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-finds-impurity-compounded-version-its-weight-loss-drug-warns-health-risks-2026-03-12/
- FDA unapproved GLP-1 concerns. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Written by: Dominia Health education
Medically reviewed by: Ariel Bowerman, BSN, R.N.
Published: September 10, 2026 · Updated: October 10, 2026
Explore Topics
Written by
Ariel Bowerman, BSN, R.N.
Content creator and writer sharing insights and stories.
